Maki P A, Sladek N E
Department of Pharmacology, University of Minnesota, Minneapolis 55455.
Biochem Pharmacol. 1993 Jan 7;45(1):231-9. doi: 10.1016/0006-2952(93)90397-f.
Several murine aldehyde dehydrogenases, most notably AHD-2, are known to catalyze the detoxification of cyclophosphamide, mafosfamide, and other oxazaphosphorines. Thus, cellular sensitivity to these agents decreases as the relevant aldehyde dehydrogenase activity increases, and vice versa. Chloral hydrate is a sedative/hypnotic agent that is sometimes administered to patients being treated with cyclophosphamide. It is known to inhibit some, but not all, aldehyde dehydrogenases. Murine (CFU-S, CFU-GEMM and CFU-Mk) and human (CFU-Mix, CFU-GM, BFU-E and CFU-Mk) hematopoietic progenitor cells, as well as murine oxazaphosphorine-resistant (L1210/OAP and P388/CLA) tumor cells, are known to contain the relevant aldehyde dehydrogenase activity but the identity of the specific enzyme present in the normal cells is unknown and may be different than that, namely AHD-2, present in neoplastic cells. In that event, the potential exists to inhibit the detoxification of the oxazaphosphorines in tumor cells without inhibiting this event in normal cells; the net effect of such a selective inhibition would be to increase the margin of safety of the oxazaphosphorines. In ex vivo experiments, chloral hydrate markedly potentiated the antitumor activity of mafosfamide against oxazaphosphorine-resistant L1210/OAP and P388/CLA cells. It did not potentiate the cytotoxic action of mafosfamide against any of the murine or human hematopoietic cells tested, even at concentrations which fully restored the sensitivity of the resistant tumor cell lines to this agent. One explanation for these observations is that hematopoietic progenitor, and the resistant tumor, cells express different relevant aldehyde dehydrogenases and that these aldehyde dehydrogenases differ in their sensitivity to inhibition by chloral hydrate. Consistent with this notion were the observations that AHD-2 was exquisitely sensitive to inhibition by chloral hydrate, whereas two other aldehyde dehydrogenases that also catalyze the detoxification of aldophosphamide, namely AHD-12a, b and AHD-13, were relatively unaffected.
已知几种小鼠醛脱氢酶,最显著的是AHD - 2,可催化环磷酰胺、马磷酰胺和其他恶唑磷的解毒作用。因此,随着相关醛脱氢酶活性的增加,细胞对这些药物的敏感性降低,反之亦然。水合氯醛是一种镇静/催眠剂,有时用于接受环磷酰胺治疗的患者。已知它能抑制部分而非全部醛脱氢酶。已知小鼠(CFU - S、CFU - GEMM和CFU - Mk)和人类(CFU - Mix、CFU - GM、BFU - E和CFU - Mk)造血祖细胞,以及小鼠恶唑磷耐药(L1210/OAP和P388/CLA)肿瘤细胞含有相关醛脱氢酶活性,但正常细胞中存在的特定酶的身份未知,可能与肿瘤细胞中存在的AHD - 2不同。在这种情况下,有可能在不抑制正常细胞中该过程的情况下抑制肿瘤细胞中恶唑磷的解毒作用;这种选择性抑制的净效应将是增加恶唑磷的安全边际。在体外实验中,水合氯醛显著增强了马磷酰胺对恶唑磷耐药的L1210/OAP和P388/CLA细胞的抗肿瘤活性。即使在能完全恢复耐药肿瘤细胞系对该药物敏感性的浓度下,它也没有增强马磷酰胺对所测试的任何小鼠或人类造血细胞的细胞毒性作用。对这些观察结果的一种解释是,造血祖细胞和耐药肿瘤细胞表达不同的相关醛脱氢酶,并且这些醛脱氢酶对水合氯醛抑制的敏感性不同。与这一观点一致的观察结果是,AHD - 2对水合氯醛的抑制极为敏感,而另外两种也催化醛磷酰胺解毒的醛脱氢酶,即AHD - 12a、b和AHD - 13,则相对不受影响。